Daniel J George, Krishnan Ramaswamy, Hongbo Yang, Qing Liu, Adina Zhang, Alexandra Greatsinger, Jasmina Ivanova, Betty Thompson, Birol Emir, Agnes Hong, Stephen J Freedland
{"title":"简单的语言总结:在现实世界中,转移性去势抵抗性前列腺癌(mCRPC)患者服用阿比特龙或恩杂鲁胺后能活多久?","authors":"Daniel J George, Krishnan Ramaswamy, Hongbo Yang, Qing Liu, Adina Zhang, Alexandra Greatsinger, Jasmina Ivanova, Betty Thompson, Birol Emir, Agnes Hong, Stephen J Freedland","doi":"10.1080/14796694.2025.2485752","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 11","pages":"1297-1306"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051579/pdf/","citationCount":"0","resultStr":"{\"title\":\"Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?\",\"authors\":\"Daniel J George, Krishnan Ramaswamy, Hongbo Yang, Qing Liu, Adina Zhang, Alexandra Greatsinger, Jasmina Ivanova, Betty Thompson, Birol Emir, Agnes Hong, Stephen J Freedland\",\"doi\":\"10.1080/14796694.2025.2485752\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\"21 11\",\"pages\":\"1297-1306\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051579/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2485752\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2485752","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.